STX-478

Cat. No.:	HY-156681		
CAS No.:	2883540-92-7		
Molecular Formula:	C ₁₆ H ₁₂ F ₅ N ₅ O ₂		
Molecular Weight:	401.29		
Target:	PI3K		
Pathway:	PI3K/Akt/m	TOR	
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

®

MedChemExpress

SOLVENT & SOLUBILITY

		Solvent Mass Concentration	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.4920 mL	12.4598 mL	24.9196 mL
		5 mM	0.4984 mL	2.4920 mL	4.9839 mL
	10 mM	0.2492 mL	1.2460 mL	2.4920 mL	

BIOLOGICAL ACTIV			
DIOLOGICAL ACTIV			
Description	STX-478 (compound 80) is an oral CNS-penetrant allosteric mutant-selective PI3Kα inhibitor. STX-478 shows robust and durable tumor regression and can be used in cancer research ^[1] .		
IC ₅₀ & Target	ΡΙ3Κα ^[1] .		
In Vitro	Vitro STX-478 (0-10,000 nM; 1 h) demonstrates selectivity for MCF10A cells harboring the H1047R kinase-domain mutation MCE has not independently confirmed the accuracy of these methods. They are for reference only. Immunofluorescence ^[1]		
	Cell Line:	MCF10A cells	
	Concentration:	0-10,000 nM	
	Incubation Time:	1 h	
	Concentration:	0-10,000 nM	

NH₂

0 ⁰

ŃН

	Result:	Targeted the MCF10A cells (with the H1047R kinase domain mutation).	
n Vivo	model ^[1] .	STX-478 (30, 100 mg/kg; p.o.; single daily for 28 days) dose-dependently reduces tumor volume in a CAL-33 xenograft mice model ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Female BALB/c nude mice (CAL-33 xenograft model) ^[1] .	
	Dosage:	30, 100 mg/kg	
	Administration:	Oral administration	
	Result:	Showed a dose-dependent reduction in tumor volume.	

REFERENCES

[1]. JR David St Jean, et al. Urea derivatives which can be used to treat cancer. Patent WO2022265993A1.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA